Updated:
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics was founded in 2000 by researchers from Tel Aviv University, with Chaim Lebovits joining as CEO to commercialize the NurOwn...
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics was founded in 2000 by researchers from Tel Aviv University, with Chaim Lebovits joining as CEO to commercialize the NurOwn platform. The wealth origin is not attributed to any single family office; the firm operates as a publicly traded biotechnology company on the NASDAQ, combining a research-driven mandate with a capital base typical of small-cap developmental stage firms. The company's strategy centers on autologous cell therapy for neurodegenerative indications, notably ALS (amyotrophic lateral sclerosis). NurOwn is their most advanced candidate, having completed a Phase III trial (NCT03280056) in 2020. Brainstorm has also explored applications in progressive multiple sclerosis and other CNS conditions. The firm collaborates with academic medical centers including the Mayo Clinic, but does not function as a traditional family office asset allocator; its deployment is R&D expenditure, not investment. Brainstorm maintains a single office in New York and has a scientific advisory board that includes leading neurologists. The company reported a net loss of approximately $16.6 million for the fiscal year 2023 (per SEC filing, 2024). In March 2024, Brainstorm announced positive topline results from a pre-specified analysis of its Phase III ALS trial, a key recent operational event (per company press release, March 2024). The firm's structural differentiator is its cell therapy platform, which is distinct from the gene-therapy and small-molecule approaches dominant in neurodegenerative disease. Additionally, its public listing imposes SEC disclosure and governance requirements that are atypical compared to the private fee structures of most family offices. This transparency profile shapes its stakeholder communication and capital strategy.
General information
Firm type
other
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Chaim Lebovits
President and Chief Executive Officer
Stacy Lindborg
Chief Development Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Brainstorm Cell Therapeutics?
The firm is led by CEO Chaim Lebovits, who oversees corporate strategy and capital allocation. Investment decisions are made by the executive team and board, which includes directors with backgrounds in biotech and finance. The firm does not operate as a family office with a dedicated CIO.
Is Brainstorm Cell Therapeutics structured as a family office or a biotech company?
Brainstorm is a publicly traded biotechnology company (NASDAQ: BCLI), not a family office. It raises capital through equity offerings, grants, and partnerships. Its primary activity is drug development, not asset management or direct portfolio investing.
What is Brainstorm Cell Therapeutics' lead asset and its current stage?
The lead asset is NurOwn, an autologous mesenchymal stem cell therapy for ALS. It has completed a Phase III trial and the company has filed for regulatory approval in the US and Europe. The technology platform also holds potential for other neurodegenerative conditions.
How does Brainstorm Cell Therapeutics source its deal flow or research pipeline?
Brainstorm develops in-house proprietary cell therapy platforms, originating from academic research at Tel Aviv University. It does not source external investments or maintain a venture deal flow. Its pipeline is entirely internal driven by scientific discovery.
What is Brainstorm's known posture on co-investments or fund commitments?
Brainstorm is not an investment entity; it does not commit capital to external funds or participate in co-investments. Its financial strategy focuses on funding its own clinical trials and operations through public market financing and collaboration agreements.
Does Brainstorm Cell Therapeutics maintain philanthropic or charitable structures?
There is no public record of Brainstorm operating a philanthropic foundation. The company's social impact is tied to its mission of developing treatments for serious diseases. It does not disclose separate charitable vehicles.
Where does the underlying funding for Brainstorm Cell Therapeutics come from?
The company funds operations through public equity offerings, at-the-market (ATM) programs, and government grants. For example, it has received funding from the California Institute for Regenerative Medicine (CIRM) and the ALS Association (per company filings and press releases).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: